scholarly journals Functional Genetic Variants on 14Q32 Associate with Death Due to Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Within One Year after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT Study)

2017 ◽  
Vol 23 (3) ◽  
pp. S99-S100
Author(s):  
Lara Sucheston-Campbell ◽  
Leah Preus ◽  
Philip L. McCarthy ◽  
Marcelo C. Pasquini ◽  
Kenan Onel ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Genetic Variants ◽  
Myeloid Leukemia ◽  
Unrelated Donor ◽  
Donor Blood ◽  
Matched Unrelated Donor ◽  
Blood And Marrow Transplantation ◽  
One Year ◽  
Acute Myeloid

Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT

Blood ◽  
2012 ◽  
Vol 119 (20) ◽  
pp. 4813-4815 ◽  
Author(s):  
Cristina Toffalori ◽  
Irene Cavattoni ◽  
Sara Deola ◽  
Sara Mastaglio ◽  
Fabio Giglio ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Patient Specific ◽  
Unrelated Donor ◽  
Matched Unrelated Donor ◽  
Leukemia Relapse ◽  
Acute Myeloid

scholarly journals Combination of Treosulfan, Fludarabine and Cytarabine as Conditioning in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms

2021 ◽  
Author(s):  
Samantha O'Hagan Henderson ◽  
Jochen J Frietsch ◽  
Inken Hilgendorf ◽  
Andreas Hochhaus ◽  
Claus-Henning Köhne ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
High Risk ◽  
Myelodysplastic Syndrome ◽  
Cumulative Incidence ◽  
Myeloid Leukemia ◽  
Myeloproliferative Neoplasms ◽  
Prospective Trial ◽  
Individual Treatment ◽  
One Year ◽  
Acute Myeloid

Abstract Treosulfan and fludarabine (Treo/Flu) were successfully introduced into toxicity-reduced conditioning for SCT. However, the risk of post-SCT relapse remains a matter of concern. We report the results of a novel individual treatment approach with Treo/Flu and cytarabine (Treo/Flu/AraC) conditioning prior to allogeneic SCT in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN).Seventy-seven patients (median age 54 years) at high risk of disease relapse due to unfavourable cytogenetics or failure to achieve complete remission prior to SCT were included. Median follow-up was 3.2 years. One-, two- and three-year RFS rates were 47.5%, 40.7%, and 37.3% and OS rates were 59.3%, 49.3%, and 45.4%, respectively. Cumulative incidence of NRM was 10% at 100 days, 18.8% at one year and 20.1% at two years. The cumulative incidence of relapse increased from 34% at one year to 41% after three years. The cumulative incidences of engraftment, chimerism, Graft-versus-host-disease (GvHD) and toxicities were acceptable and comparable with similar patients conditioned with Treo/Flu or FLAMSA-RIC. In conclusion, Treo/Flu/AraC provides tolerable, feasible and effective conditioning for patients with AML, MDS or MPN, even in advanced disease states. The incidence of NRM and relapse is acceptable in this heavily pre-treated population with high-risk disease. Future research will aim to confirm these initial findings and include a larger number of participants in a prospective trial.

Sign in / Sign up

Export Citation Format

Share Document